Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk
暂无分享,去创建一个
F. Martinez | R. Brook | B. Celli | J. Vestbo | J. Yates | D. Newby | P. Calverley | C. Crim | Julie A. Anderson | R. Wise | Natacha Gallot | S. Kilbride | J. Anderson
[1] F. Martinez,et al. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction , 2017, American journal of respiratory and critical care medicine.
[2] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[3] P. Barnes. Sex Differences in Chronic Obstructive Pulmonary Disease Mechanisms. , 2016, American journal of respiratory and critical care medicine.
[4] P. Calverley,et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD , 2016, European Respiratory Journal.
[5] J. Soriano,et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.
[6] A. Dirksen,et al. Analysis of FEV1 Decline in Relatively Healthy Heavy Smokers: Implications of Expressing Changes in FEV1 in Relative Terms , 2014, COPD.
[7] B. Celli,et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes , 2013, European Respiratory Journal.
[8] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[9] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[10] Satoshi Konno,et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[11] F. Martinez,et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.
[12] L. Edwards,et al. Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.
[13] P. Calverley,et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study , 2011, The clinical respiratory journal.
[14] P. Calverley,et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. , 2010, American journal of respiratory and critical care medicine.
[15] Liam Ck. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial , 2010 .
[16] J. Hankinson,et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. , 2010, Chest.
[17] D. Postma,et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. , 2009, Annals of internal medicine.
[18] M. Decramer,et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.
[19] J. Soriano,et al. Investigating the natural history of lung function: facts, pitfalls, and opportunities. , 2009, Chest.
[20] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[21] I. Pavord,et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.
[22] N. Pride,et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. , 2005, American journal of respiratory and critical care medicine.
[23] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[24] E. R. Sutherland,et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis , 2003, Thorax.
[25] S. Spencer,et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. , 2003, Chest.
[26] J. Connett,et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.
[27] Helen Brown,et al. Applied Mixed Models in Medicine , 2000, Technometrics.
[28] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[29] tefan,et al. LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .
[30] W. Bailey,et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.
[31] J. Vestbo,et al. L o n g - t e r m effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised c o n t r o l l e dt r i a l , 1999 .
[32] J L Hankinson,et al. Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.
[33] J. Vestbo,et al. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.
[34] W. Bailey,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.
[35] A. Woolcock,et al. Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers in Busselton, Western Australia. , 1990, Thorax.
[36] P. Schnohr,et al. Effects of smoking and changes in smoking habits on the decline of FEV1. , 1989, The European respiratory journal.
[37] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.